Amneal Pharmaceuticals, Inc. (AMRX) Balance Sheet

The swing from negative to positive equity appears largely attributable to the step-up in total assets to $5.3B, which coincides with a sharp rise in goodwill to $2.3B and debt rising in parallel. This pattern suggests the improvement in book equity may reflect acquisition accounting rather than accumulated operating earnings, since retained earnings remain deeply negative through 2026Q2. Investors should monitor whether asset growth is being financed by debt in a way that keeps the balance sheet structurally strained.

Leverage is extreme relative to the equity cushion, and the cash position covers only a small fraction of total debt, which limits flexibility if refinancing conditions tighten. Interest costs appear to absorb a meaningful share of operating income, consistent with the thin net margin observed in prior analysis. The debt profile therefore warrants close monitoring rather than being treated as a strategic, low-cost funding source.

A current ratio above 1.0 provides a nominal buffer, but the low absolute cash balance relative to a $3.3B debt load means liquidity depends heavily on receivables and inventory conversion. Prior cash flow analysis showed working capital absorbing large amounts of cash in 2026Q1 and 2026Q2, which implies the liquidity cushion could erode if collections slow. The buffer appears adequate on paper but thin in practice.

The jump in goodwill implies recent acquisition activity consistent with the $420.6M in net acquisition outflows noted in cash flow analysis. A goodwill balance this large relative to equity means any future impairment could materially reduce book value and further pressure the already fragile equity position. Investors should view the asset quality as heavily dependent on the successful integration and performance of acquired businesses.